24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TEMALIEVA 100 MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TEMALIEVA 100 MG |
|---|---|
| Composition | Temozolomide Capsules IP 100 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (5 cap) |
| Country of Origin | India |
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is a prescription anticancer medicine containing Temozolomide 100 mg, an oral chemotherapy drug widely used in the treatment of certain malignant brain tumors. It belongs to a class of medicines known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from growing, multiplying, and spreading.
Brain tumors are among the most complex cancers to treat due to their location within the central nervous system. One of the major advantages of Temozolomide is its ability to cross the blood-brain barrier, allowing it to directly target cancer cells within the brain. This characteristic has made Temozolomide a cornerstone treatment in modern neuro-oncology.
TEMALIEVA 100 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), the most aggressive type of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used as part of initial treatment, maintenance therapy, or recurrent tumor management depending on the patient's condition and oncologist's recommendations.
Unlike many traditional chemotherapy medicines that require intravenous administration, TEMALIEVA 100 MG is available in capsule form, making treatment more convenient for eligible patients while supporting long-term cancer management.
Temozolomide has become an important component of comprehensive brain cancer treatment programs because it can be used alone or alongside radiation therapy to improve disease control and treatment outcomes.
TEMALIEVA 100 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular medical supervision, including complete blood count monitoring, liver function assessments, infection screening, and clinical evaluations to ensure safe and effective treatment.
Due to its proven effectiveness in brain tumor management, TEMALIEVA 100 MG has become a trusted treatment option in oncology centers worldwide.
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is primarily used in the treatment and management of malignant brain tumors.
The medicine is widely used in newly diagnosed and recurrent glioblastoma patients.
Temozolomide is commonly prescribed for patients with anaplastic astrocytoma after surgery or radiation therapy.
The medicine forms an important part of comprehensive brain cancer treatment strategies.
Doctors may recommend Temozolomide when brain tumors return after previous therapies.
The medicine may be prescribed as maintenance treatment to help control tumor progression.
Temozolomide is often used alongside radiation therapy to enhance treatment effectiveness.
The medicine is an integral component of modern neuro-oncology treatment protocols.
Temozolomide belongs to a class of medicines known as Alkylating Agents.
TEMALIEVA works by:
This targeted action helps reduce the ability of cancer cells to survive and spread within the brain.
Like all medicines, TEMALIEVA 100 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Nausea is one of the most frequently reported side effects.
Some patients may experience vomiting during treatment.
Weakness and tiredness are common during chemotherapy.
Reduced appetite may affect daily nutritional intake.
Digestive disturbances such as constipation may occur.
Some individuals may experience headaches during therapy.
Temporary hair thinning or hair loss may develop.
Temozolomide may reduce white blood cells, red blood cells, and platelet counts.
Occasional dizziness may occur during treatment.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the specific diagnosis.
Temozolomide dosing is often calculated using body surface area.
Regular monitoring helps determine appropriate dosage adjustments.
Doctors may modify treatment based on effectiveness and tolerability.
Concurrent radiation therapy and other medicines may influence dosing schedules.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medications, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of glioblastoma multiforme, anaplastic astrocytoma, and certain malignant brain tumors.
Temozolomide is an oral chemotherapy medicine that works by damaging cancer cell DNA and slowing tumor growth.
Yes. Temozolomide is a chemotherapy medicine belonging to the alkylating agent class.
Yes. It can effectively reach brain tissue, making it useful for treating brain tumors.
Yes. It is commonly prescribed alongside radiation therapy for newly diagnosed glioblastoma.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring regular monitoring.
Yes. Blood tests, liver function monitoring, and routine clinical evaluations are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and neuro-oncology treatment.